UNQUOTE

Grok among VCs in $100m Juvenescence series-B

  • LinkedIn  
  • Google plus  

VC firms including Grok Ventures have provided UK-based biotechnology company Juvenescence with a $100m series-B funding round.

The firm received $10m from its founders and an additional $10m from four cornerstone investors, including Grok, the investment company of Atlassian co-founder Mike Cannon-Brookes. Michael Spencer's private investment company, IPGL, was another of the  cornerstone investors.

The money from this latest round will provide working capital to progress many of the company's programmes. Juvenescence has raised a total of $165m in the past 18 months and will look to undertake an IPO in the near future. 

Company
Juvenescence is a life sciences company that invests in technology to combat diseases. The group works with scientists and drug developers, as well as machine learning experts.

People
Juvenescence – Greg Bailey (CEO); Jim Mellon (chair)

 

  • LinkedIn  
  • Google plus  

More on Expansion

Latest News